4D Molecular Therapeutics Inc. Stock Price, News & Analysis

4D Molecular Therapeutics (NASDAQ: FDMT) reported its first quarter 2022 financial results, highlighting key clinical advancements in its pipeline. The firm initiated the treatment of the first patient with 4D-150 for wet AMD and dosed the first patient in a Phase 1/2 trial for 4D-710 targeting cystic fibrosis. Despite these developments, total revenue decreased to $1.2 million from $2.0 million year-over-year. R&D expenses rose to $19.4 million, contributing to a net loss of $26.3 million. The company maintains a strong cash position of $284.5 million, expected to fund operations into 2024.

4D Molecular Therapeutics, Inc. (Nasdaq: FDMT) will participate in the 2022 Bank of America Healthcare Conference on May 10, 2022, at 8:40 a.m. PT. The event will feature a fireside chat, accessible via a live audio webcast on the 4DMT website. This clinical-stage biotherapeutics company focuses on genetic medicines and has developed targeted vectors for five clinical products addressing diseases in ophthalmology, cardiology, and pulmonology, including Fabry disease and cystic fibrosis.

4D Molecular Therapeutics (Nasdaq: FDMT) has initiated its Phase 1/2 clinical trial for 4D-710, focusing on treating cystic fibrosis. The first patient has been dosed, marking a significant milestone for the company. This therapy aims to deliver CFTR expression to lung cells, potentially benefiting a wide range of cystic fibrosis patients, especially those unable to use existing treatments. The trial will assess safety, tolerability, and clinical activity, with around 18 patients expected to participate.

4D Molecular Therapeutics (Nasdaq: FDMT) reported 2021 financial results with total revenue of $18 million, up from $13.6 million in 2020, driven by a Roche collaboration. The company provided clinical data updates on three key programs, including 4D-310 for Fabry disease, showing promising results. Two additional programs have entered clinical development. The company ended 2021 with $315 million in cash, expected to fund operations through mid-2024. Despite increased R&D and G&A expenses, the net loss grew to $71.3 million from $56.7 million in 2020.

On February 22, 2022, 4D Molecular Therapeutics (Nasdaq: FDMT) announced the resignation of Professor David Schaffer, Ph.D., from its board of directors. This transition comes as the company evolves into a clinical-stage gene therapy firm, with five products currently in development. Professor Schaffer, who has served on the board since 2013, is taking up new roles at UC Berkeley, while emphasizing the company’s strengthened board with new independent directors. 4DMT aims to leverage its Therapeutic Vector Evolution platform for gene therapy innovations in ophthalmology, cardiology, and pulmonology.

4D Molecular Therapeutics (Nasdaq: FDMT), a clinical-stage gene therapy company, announced participation in the 11th Annual SVB Leerink Global Healthcare Conference, scheduled for February 16, 2022, at 2:00 p.m. PT. The event will take the form of a fireside chat, and a live audio webcast will be accessible through the company’s website, with a replay available for two weeks post-event. 4DMT focuses on targeted gene therapies, currently developing five clinical-stage products for conditions including Fabry disease, wet AMD, and cystic fibrosis.

4D Molecular Therapeutics (Nasdaq: FDMT) has released interim data from its ongoing Phase 1/2 trial of 4D-310 for treating Fabry disease. The results indicate stable alpha-galactosidase A (AGA) activity among patients after discontinuing enzyme replacement therapy (ERT), with levels at 14-fold and 10-fold the normal range. Additionally, improvements were noted in cardiac imaging and quality-of-life scores. The trial aims to confirm safety and tolerability while assessing AGA activity and cardiac function.

4D Molecular Therapeutics (FDMT) announced updated interim clinical data for its 4D-310 Phase 1/2 trial aimed at treating Fabry disease. The presentation is scheduled for February 9, 2022, at the 18th Annual WORLD Symposium. 4D-310 utilizes the evolved C102 vector to deliver a functional GLA gene, potentially addressing unmet medical needs in Fabry patients suffering from life-threatening complications. The trial aims to demonstrate improved AGA enzyme levels, enhancing patients' quality of life and offering a novel therapeutic option beyond current enzyme replacement therapies.

4D Molecular Therapeutics (NASDAQ: FDMT) received Fast Track Designation from the FDA for its product candidate 4D-125 to treat inherited retinal dystrophies caused by defects in the RPGR gene. This designation aims to expedite development for serious conditions lacking approved treatments, providing 4DMT with closer communication with the FDA. 4D-125 is currently in a Phase 1/2 clinical trial to assess safety and clinical activity, catering to the urgent need for therapies for X-linked Retinitis Pigmentosa (XLRP), which affects an estimated 24,000 patients in the U.S. alone.